Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment
NCT ID: NCT07149259
Last Updated: 2025-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2025-06-18
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
At Home Device Utilization
eSight Go device will be utilized at home for a total of 4 weeks in environments the participant feels comfortable using it (e.g. home, work, stores).
At Home Use
Participants will take the device home for 4 weeks to use in daily living, such as the home and community settings. There will be regular follow-up phone calls once per week from a member of the research team (e.g., an occupational therapist, or low vision therapist) who is familiar with the device to assist with possible troubleshooting as well as device use strategies. The follow up calls will also collect information about device use time and activities. The device will be returned at visit 2.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
At Home Use
Participants will take the device home for 4 weeks to use in daily living, such as the home and community settings. There will be regular follow-up phone calls once per week from a member of the research team (e.g., an occupational therapist, or low vision therapist) who is familiar with the device to assist with possible troubleshooting as well as device use strategies. The follow up calls will also collect information about device use time and activities. The device will be returned at visit 2.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Best-corrected visual acuity between 20/50 to 20/400 in the better eye.
* Subjects who have been diagnosed with an ocular condition causing visual impairment
* Have a functional binocular field of view of at least 20 degrees.
* Visual status stable for at least six months.
* Demonstrate visual benefit from magnification.
* Agree to wear the eSight Go in a variety of situations in the home and community.
* Score ≥ 20 on the Short Orientation-Memory-Concentration Test of Cognitive Impairment (OMCT).
* Subject must be able to provide an informed consent
* Subject must agree to use eSight Eyewear only under conditions that will not jeopardize the safety of either the user or the device.
Exclusion Criteria
* Participants who have undergone cataract, refractive, or other surgical procedures related to vision in the six-month period prior to study enrollment.
* Severe (\>20/400) visual impairment in the better seeing eye.
* Cognitive limitations (\< 20 on OMCT).
* Participants who have undergone any vision-related injections (e.g. anti-VEGF) in the two-month period prior to the study because of active bleeding in the retina. Ongoing anti-VEGF treatments are permitted if the participant is in a "Treat and Extend" or pro re nata ("PRN") disease management, and macula is dry.
* Participants are unable or unwilling to adhere to the examination schedules as they are described in the study protocol. This may also include participants already enrolled, who for whatever reason, have become unable or unwilling to continue the study. This may also include participants for whom the travel time to/from the study site is unacceptable.
* Participants who self-report a history of alcoholism, drug abuse, or psychosis.
* Participants who exhibit clinical evidence of depression, poor motivation, emotional or intellectual problems, or any other conditions which would likely limit validity of consent or appropriate responses to participate in the study or who are deemed unsuitable psychologically or physiologically for study participation by the investigator.
* Participants who may have a conflict of interest with eSight Corp, which could reasonably influence their participation in the study.
* Refractive error outside the range correctable by lens inserts in the device (\> +/-8.00 D sph or -4.00 cyl)
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brooks Rehabilitation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Katelyn Jordan
Director of Vision Rehab Services
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katelyn Jordan, D.O.
Role: PRINCIPAL_INVESTIGATOR
Brooks Rehabilitation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brooks Rehabilitation
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hannah Grimes
Role: primary
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO00085670
Identifier Type: -
Identifier Source: org_study_id